TG Therapeutics (TGTX) FY2021 results: revenue $7 million, up 4300.7% on the year
TG Therapeutics, Inc. (TGTX) reported revenue of $7 million for fiscal 2021, the year ended 31 December 2021, up 4300.7% on the year before. Net income was -$348 million, and diluted earnings per share $-2.63. The figures are the company's own, from the 10-K it filed with the SEC on 1 March 2022.
Revenue
$7 million
+4,300.7% on the year
FY2016FY2021
Operating margin
-5154.3%
-179996.1% a year earlier
FY2016FY2021
Net income
-$348 million
FY2016FY2021
Diluted EPS
-$2.63
FY2016FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
-296
-215
-133
Capital expenditure
0.4
0.4
0.1
+12.3%
Free cash flow
-296
-215
-133
Free cash flow margin
-4425.7%
-141357.9%
-87458.6%
Cash from investing
-0.3
-24.5
-0.7
Cash from financing
41.4
680
204
-93.9%
Depreciation and amortisation
0.3
0.4
0.3
-24.6%
Share-based compensation
61.3
80.3
11.3
-23.7%
Diluted shares, weighted
132m
115m
n/a
+14.6%
Shares outstanding at period end
143m
141m
109m
+1.9%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
237
519
38.6
-54.3%
Debt
67.8
29.9
29.0
+126.7%
Operating lease liabilities
9.8
10.4
10.2
-5.4%
Other liabilities
64.9
66.0
85.2
-1.7%
Total liabilities and equity
380
626
163
-39.3%
Fixed assets
0.6
0.5
0.3
+24.7%
Goodwill
0.8
0.8
0.8
0.0%
Investments
51.4
52.0
27.8
-1.1%
Cash and equivalents
299
553
113
-46.0%
Receivables
1.4
n/a
n/a
Other assets
26.5
18.9
21.5
+40.2%
Total assets
380
626
163
-39.3%
10-K for the year ended 31 December 2021, filed 1 March 2022: the filing.